Briefs: Hikal and Sun Pharma
Sun Pharma gets 8 observations from USFDA for Halol facility
Sun Pharma gets 8 observations from USFDA for Halol facility
This strategic expansion marks a significant step in the company's global growth strategy
Launches FSSAI’s inclusive campaign to stop obesity with multilingual, sign language outreach and multi-platform media engagement under Eat Right India programme
Annual EBITDA margin expands by 170 basis points
Akums invested Rs. 272 crore in capital expenditure during FY25
Sun Pharma will invest up to $25 million in US-based Pharmazz Inc, raising its stake to 22.7%
Standalone profit from operations for the quarter were Rs. 162 crores
Scores highest PAT of Rs. 118 crore in FY25
Delivers robust earnings performance, successfully navigating a dynamic environment
Subscribe To Our Newsletter & Stay Updated